CGEM Quote, Financials, Valuation and Earnings

Black Diamond Therapeutics, Inc. has a net margin of -- compared to Cullinan Therapeutics, Inc.'s net margin of 80.77%. Cullinan Therapeutics, Inc.'s return on equity of -39.95% beat Black Diamond Therapeutics, Inc.'s return on equity of 18.5%.

Cullinan Therapeutics, Inc. has a consensus price target of $29.08, signalling upside risk potential of 200.39%. On the other hand Black Diamond Therapeutics, Inc. has an analysts' consensus of $9.25 which suggests that it could grow by 271.2%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Cullinan Therapeutics, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Cullinan Therapeutics, Inc..

Cullinan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Black Diamond Therapeutics, Inc. has a beta of 3.331, suggesting its more volatile than the S&P 500 by 233.083%.

Cullinan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Black Diamond Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cullinan Therapeutics, Inc. pays -- of its earnings as a dividend. Black Diamond Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cullinan Therapeutics, Inc. quarterly revenues are --, which are smaller than Black Diamond Therapeutics, Inc. quarterly revenues of --. Cullinan Therapeutics, Inc.'s net income of -$50.6M is lower than Black Diamond Therapeutics, Inc.'s net income of -$8.5M. Notably, Cullinan Therapeutics, Inc.'s price-to-earnings ratio is -- while Black Diamond Therapeutics, Inc.'s PE ratio is 7.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cullinan Therapeutics, Inc. is -- versus 2.07x for Black Diamond Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Cullinan Therapeutics, Inc.'s net margin of --. Cullinan Therapeutics, Inc.'s return on equity of -39.95% beat CEL-SCI Corp.'s return on equity of -266.61%.

Cullinan Therapeutics, Inc. has a consensus price target of $29.08, signalling upside risk potential of 200.39%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Cullinan Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Cullinan Therapeutics, Inc..

Cullinan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Cullinan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cullinan Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Cullinan Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Cullinan Therapeutics, Inc.'s net income of -$50.6M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Cullinan Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cullinan Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Cullinan Therapeutics, Inc.'s net margin of -953.4%. Cullinan Therapeutics, Inc.'s return on equity of -39.95% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Cullinan Therapeutics, Inc. has a consensus price target of $29.08, signalling upside risk potential of 200.39%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than Cullinan Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Cullinan Therapeutics, Inc..

Cullinan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Cullinan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cullinan Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Cullinan Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Cullinan Therapeutics, Inc.'s net income of -$50.6M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Cullinan Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cullinan Therapeutics, Inc. is -- versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Cullinan Therapeutics, Inc.'s net margin of -255.85%. Cullinan Therapeutics, Inc.'s return on equity of -39.95% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Cullinan Therapeutics, Inc. has a consensus price target of $29.08, signalling upside risk potential of 200.39%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Cullinan Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cullinan Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Cullinan Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Cullinan Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cullinan Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cullinan Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cullinan Therapeutics, Inc.'s net income of -$50.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cullinan Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cullinan Therapeutics, Inc. is -- versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.